Long-term suppressive effect of octreotide on progression of metastatic gastrinoma with multiple endocrine neoplasia type 1: seven-year follow up.

Abstract

A 30-year-old woman had a history of prolactinoma and primary hyperparathyroidism. She was diagnosed as having multiple endocrine neoplasia type 1 with gastrinoma and liver metastases. Octreotide therapy was started and the serum gastrin level decreased immediately. Octreotide continued to suppress gastrin secretion over the next 7 years. The Ki67/MIB1 proliferation index of this tumor was only 0.5 % and somatostatin receptor (SSTR) 2 expression was very strong in both 2002 and 2009. This case suggests the importance of investigating the Ki67/MIB1 index and SSTR expression in patients with metastatic gastrinoma.

• Authors: Megu Yamaguchi, Yuya Yamada, Yoshiya Hosokawa, Ryuya Iwamoto, Sachiko Tamba, Arisa Ihara, Koji Yamamoto, Yoshihiko Hoshida, Yuji Matsuzawa
• Journal: Internal medicine (Tokyo, Japan) (Intern Med) Vol. 49 Issue 15 Pg. 1557-63 ( 2010) ISSN: 1349-7235 [Electronic] Japan
• PMID: 20686291 (Publication Type: Case Reports, Journal Article)

Chemical References

• Octreotide

Topics

• Adult
• Disease Progression
• Female
• Follow-Up Studies
• Gastrinoma (diagnosis, drug therapy)
• Humans
• Multiple Endocrine Neoplasia Type 1 (diagnosis, drug therapy)
• Octreotide (administration & dosage)
• Pancreatic Neoplasms (diagnosis, drug therapy)
• Time Factors